Stock ANIP ANI PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company ANI Pharmaceuticals, Inc.

Equities

ANIP

US00182C1036

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
64.58 USD -1.37% Intraday chart for ANI Pharmaceuticals, Inc. -5.18% +17.12%
Apr. 17 Ani Pharmaceuticals Insider Sold Shares Worth $1,500,589, According to a Recent SEC Filing MT
Apr. 09 ANI Pharmaceuticals, Inc. Announces the Launch of Baclofen Oral Suspension CI

Business Summary

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of 116 products with a variety of indications and a robust portfolio of pipeline products. It has acquired the NDAs for and market Atacand, Atacand HCT, Arimidex, Casodex, Lithobid, Vancocin, Inderal LA, Inderal XL, InnoPran XL, Oxistat, Veregen, and Pandel. The Company sources the raw materials for its products from both domestic and international suppliers.

Number of employees: 642

Sales per Business

USD in Million2022Weight2023Weight Delta
Generics, Established Brands, and Other
77.0 %
275 86.8 % 375 77.0 % +36.40%
Rare Disease
23.0 %
42 13.2 % 112 23.0 % +168.95%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
99.9 %
312 98.7 % 486 99.9 % +55.64%
Canada
0.1 %
4 1.3 % 1 0.1 % -85.73%

Managers

Managers TitleAgeSince
Nikhil Lalwani CEO
 Chief Executive Officer 46 20-09-07
Stephen Carey DFI
 Director of Finance/CFO 53 16-05-05
Patrick Walsh CHM
 Chairman 63 18-05-16
Elizabeth Powell CMP
 Compliance Officer - 22-02-23
Mary Pao CTO
 Chief Tech/Sci/R&D Officer - 22-02-23
Muthusamy Shanmugam CTO
 Chief Tech/Sci/R&D Officer 56 21-11-18
James Marken COO
 Chief Operating Officer 61 07-02-28
Krista Davis HRO
 Human Resources Officer 51 22-09-11
Meredith Cook LAW
 General Counsel 50 22-07-17
Ori Gutwerg PRN
 Corporate Officer/Principal 50 -

Members of the board

Members of the board TitleAgeSince
Thomas Haughey BRD
 Director/Board Member 60 18-04-30
Antonio Pera BRD
 Director/Board Member 66 20-08-05
David Nash BRD
 Director/Board Member 68 18-09-30
Patrick Walsh CHM
 Chairman 63 18-05-16
Renee Tannenbaum BRD
 Director/Board Member 72 22-03-21
Jeanne A. Thoma BRD
 Director/Board Member 65 20-08-05
Muthusamy Shanmugam CTO
 Chief Tech/Sci/R&D Officer 56 21-11-18
Nikhil Lalwani CEO
 Chief Executive Officer 46 20-09-07
Matthew Leonard BRD
 Director/Board Member 58 23-08-20

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 10,864 0 0 80.97 %
Stock B 1 21,244,250 17,211,113 ( 81.02 %) 263,943 ( 1.242 %)
Stock C 0 25,000 0 0

Shareholders

NameEquities%Valuation
BlackRock Advisors LLC
11.51 %
2,424,564 11.51 % 168 M $
Meridian Venture Partners LLC
6.737 %
1,419,381 6.737 % 98 M $
Vanguard Fiduciary Trust Co.
6.118 %
1,288,972 6.118 % 89 M $
Rubric Capital Management LP
5.340 %
1,125,000 5.340 % 78 M $
Muthusamy Shanmugam
4.194 %
883,504 4.194 % 61 M $
Deep Track Capital LP
2.848 %
600,000 2.848 % 41 M $
STATE STREET CORPORATION
2.812 %
592,423 2.812 % 41 M $
Dimensional Fund Advisors LP
2.809 %
591,731 2.809 % 41 M $
Global Alpha Capital Management Ltd.
2.764 %
582,428 2.764 % 40 M $
William Blair Investment Management LLC
2.328 %
490,557 2.328 % 34 M $
NameEquities%Valuation
Angela Ho
25.56 %
2,777 25.56 % 191 974 $
Louis Sullivan
25.56 %
2,777 25.56 % 191 974 $
Hans Jebsen
25.56 %
2,777 25.56 % 191 974 $
Marcus Jebsen
12.78 %
1,388 12.78 % 95 952 $

Company contact information

ANI Pharmaceuticals, Inc.

210 Main Street West

56623, Baudette

+218 634 3500

http://www.anipharmaceuticals.com
address ANI Pharmaceuticals, Inc.(ANIP)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Ratings for ANI Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
64.58 USD
Average target price
79.8 USD
Spread / Average Target
+23.57%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ANI PHARMACEUTICALS, INC. Stock ANI Pharmaceuticals, Inc.
+17.12% 1.35B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+27.97% 672B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+23.58% 550B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.02% 351B
MERCK & CO., INC. Stock Merck & Co., Inc.
+14.85% 317B
ABBVIE INC. Stock AbbVie Inc.
+6.25% 292B
ASTRAZENECA PLC Stock AstraZeneca PLC
+2.96% 211B
NOVARTIS AG Stock Novartis AG
-0.41% 203B
ROCHE HOLDING AG Stock Roche Holding AG
-10.02% 194B
PFIZER, INC. Stock Pfizer, Inc.
-11.81% 144B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ANIP Stock
  4. Company ANI Pharmaceuticals, Inc.